Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Altamira Therapeutics’ (NASDAQ: CYTO) Clinical Data on Bentrio Showing Strong Nasal Residence and Rheological Properties

Altamira Therapeutics, Ltd. (NASDAQ: CYTO) is engaged within the research and development of RNA-based therapies for extrahepatic targets and unmet medical needs. Shares of the therapeutics company are rallying 46% through early trading on Friday, March 3, 2023. Over the past three months, Altamira Therapeutics has seen average daily volume of 41,430 shares. However, volume of 16.73 million shares or dollar volume of around $62.57 million, has already exchanged hands through early trading.

Shares of Altamira Therapeutics are gaining after the company announced data from a recent peer-reviewed clinical study involving the company’s Bentrio nasal spray versus a saline control. The study involved comparing Bentrio’s residence time and rheological properties compared to the standard saline solution.

The data demonstrated Bentrio’s superior nasal residence time of up to 3.5 hours compared to the saline control group. Bentrio was shown to be safe and well-tolerable, while the extended nasal residence time is seen as protective to nasopharyngeal areas. This is important because Bentrio’s extended nasal residence time supports protection against allergies and other airborne particles.

Altamira Therapeutics conducted the study on eight healthy volunteers who were given either Bentrio or a traditional saline nasal spray marked with a fluorescent agent to track distribution and residence time. Volunteers given Bentrio were found to have the spray widely distributed throughout the lower and middle parts of the nasal cavity. Researchers were able to detect the Bentrio protective film for up to 240 minutes, compared to the saline group’s 60 minute nasal residence time.

“Importantly, the formulation also reached the oropharynx, remaining in place for up to 240 min compared with 60 min in the control group. This feature is particularly important, since airborne viruses and allergens come into contact with both the nasal mucosa and oropharyngeal cavity,” noted the published peer-reviewed study.

The study’s results were published in Drug Development and Industrial Pharmacy, which can be viewed here: https://www.tandfonline.com/doi/full/10.1080/03639045.2023.2183724

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Altamira Therapeutics’ (NASDAQ: CYTO) Clinical Data on Bentrio Showing Strong Nasal Residence and Rheological Properties appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.